Cargando…
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the paucity of human-relevant models for target discovery and compound screening. Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different trigger...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635827/ https://www.ncbi.nlm.nih.gov/pubmed/36823355 http://dx.doi.org/10.1038/s41587-023-01680-4 |